Nicole Romeo
Acute Care · New York, NYNPI 1982170650
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Pfizer at 35.3% of the total. Reporting peaked in 2021 at $333 and has fallen 68.0% since, to $107 in 2025.
Across 47 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$372
- Boehringer Ingelheim$243
- Johnson & Johnson$182
- Novartis$67
- AstraZeneca$59
- AbbVie$52
- plus $78 from 3 others
What the payments were for
- Food & beverage$1,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $372 |
| Boehringer Ingelheim | 9 | $243 |
| Johnson & Johnson | 8 | $182 |
| Novartis | 3 | $67 |
| AstraZeneca | 3 | $59 |
| AbbVie | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Gilead | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $16 |
How this compares
$1,053 in reported general payments places this provider in the 80th percentile of 980 acute care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefpodoxime Proxetil | 15 | $473 |
| Metoprolol Succinate | 14 | $275 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Julie Anne RoldanNew York$10K
- Lauren Dela CruzNew York$9K
- Kristen DonchezNew York$8K
- Tracy Valerie BertizNew York$7K
- Jennifer UllmanNew York$7K
- Sara-Jane DakroubNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.